- Home
- HLNE vs RYTM Comparison
HLNE vs RYTM Comparison
Compare HLNE & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLNE
- RYTM
- Stock Information
- Founded
- HLNE 1991
- RYTM 2008
- Country
- HLNE United States
- RYTM United States
- Employees
- HLNE N/A
- RYTM N/A
- Industry
- HLNE Investment Managers
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- HLNE Finance
- RYTM Health Care
- Exchange
- HLNE Nasdaq
- RYTM Nasdaq
- Market Cap
- HLNE 5.6B
- RYTM 6.4B
- IPO Year
- HLNE 2017
- RYTM 2017
- Fundamental
- Price
- HLNE $118.13
- RYTM $111.42
- Analyst Decision
- HLNE Hold
- RYTM Strong Buy
- Analyst Count
- HLNE 9
- RYTM 13
- Target Price
- HLNE $162.11
- RYTM $109.77
- AVG Volume (30 Days)
- HLNE 567.0K
- RYTM 607.5K
- Earning Date
- HLNE 11-04-2025
- RYTM 11-04-2025
- Dividend Yield
- HLNE 1.79%
- RYTM N/A
- EPS Growth
- HLNE 18.07
- RYTM N/A
- EPS
- HLNE 5.15
- RYTM N/A
- Revenue
- HLNE $692,190,000.00
- RYTM $156,287,000.00
- Revenue This Year
- HLNE $5.18
- RYTM $46.14
- Revenue Next Year
- HLNE $17.29
- RYTM $63.37
- P/E Ratio
- HLNE $23.37
- RYTM N/A
- Revenue Growth
- HLNE 10.66
- RYTM 53.55
- 52 Week Low
- HLNE $114.63
- RYTM $45.91
- 52 Week High
- HLNE $203.72
- RYTM $109.58
- Technical
- Relative Strength Index (RSI)
- HLNE 29.87
- RYTM 73.42
- Support Level
- HLNE $114.63
- RYTM $97.97
- Resistance Level
- HLNE $127.26
- RYTM $102.92
- Average True Range (ATR)
- HLNE 4.47
- RYTM 3.57
- MACD
- HLNE -0.49
- RYTM 1.15
- Stochastic Oscillator
- HLNE 13.58
- RYTM 87.69
About HLNE Hamilton Lane Incorporated
Hamilton Lane Inc is a private market investment solutions provider in the United States. It works with its clients to conceive, structure, build out, manage and monitor portfolios of private markets funds and direct investments, and it helps them access a set of such investment opportunities around the world. The company offers a range of investment solutions across a range of private markets, including private equity, private credit, real estate, infrastructure, natural resources, growth equity, venture capital and impact. The company generate revenues mainly from management and advisory fees.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.